PX 128
Alternative Names: PX-128Latest Information Update: 01 Jul 2024
At a glance
- Originator Proteologix
- Developer Johnson & Johnson
- Class Anti-inflammatories; Antiasthmatics; Bispecific antibodies; Skin disorder therapies
- Mechanism of Action Interleukin 13 inhibitors; Thymic stromal lymphopoietin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Asthma; Atopic dermatitis